ASAP2 Antibody - Primary antibody, specific to ASAP2, Rabbit IgG

Cat. No.: Ab089761

GRADE & PURITY ExactAb™, Validated, 1.0 mg/mL

Application

WB

Host species

Rabbit

Reactive species

Human, Mouse

Isotype

Rabbit IgG

Conjugation

Unconjugated

Visão geral

Rabbit anti Human ASAP2 Antibody, Polyclonal, could be used for WB and so on.
Application:
WB: 1/500-1/2000
Protein Function:
Activates the small GTPases ARF1, ARF5 and ARF6. Regulates the formation of post-Golgi vesicles and modulates constitutive secretion. Modulates phagocytosis mediated by Fc gamma receptor and ARF6. Modulates PXN recruitment to focal contacts and cell migration.

Specifications

Product Name

ASAP2 Antibody - Primary antibody, specific to ASAP2, Rabbit IgG

Especificações e pureza

ExactAb™, Validated, 1.0 mg/mL

Espécie hospedeira

Rabbit

Especificidade

ASAP2

Imunogénio

A synthetic peptide derived from human ASAP2 (AA 640-720).

Controlo positivo

WB: A431, Raji and HEK293 cell lysates.

Conjugação

Unconjugated

Grau

ExactAb™, Validated

Isótipo

Rabbit IgG

SDS-PAGE

150 kDa

Método de purificação

Immunogen affinity purified

Concentração

1.0 mg/mL

Product Line

Produtos biológicos

Armazenamento e envio

Forma

Liquid

Condições de armazenamento de armazenamento

Store at -20°C,Avoid repeated freezing and thawing

Enviado em

Ice chest + Ice pads

Estabilidade e armazenamento

Store at 4℃ short term (1-2 weeks). Store at -20℃ long term (12 months). Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Imagens

Western Blot: ASAP2 Antibody (Ab089761)

ASAP2 Antibody (Ab089761) - Western Blot
All lanes: ASAP2 Antibody (Ab089761) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) at 1/10000 dilution

Predicted band size: 112 kDa
Observed band size: 106, 112 kDa
ASAP2 Antibody (Ab089761) recognizes two isoforms of ASAP2.
Exposure time: 100.0 s

Aplicação

Aplicação

Dilution info

WB

1/500-1/2000

Alvos associados (humanos)

ASAP2 Tbio Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 (0 Activities)

Discover Target: ASAP2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Application Protocols

Tested applications, recommended dilutions, positive control samples, and detailed protocols are Not specified for this item; refer to CoA/Spec Sheet.

Note: This section is intentionally limited to product‑specific information per catalog policy. For general assay guidance, see Reaction & Applications and Buffer Applications.

Biological Roles

This antibody targets ASAP2 (ArfGAP with SH3 domain, Ankyrin repeat and PH domain–containing protein 2). The following summarizes ASAP2 biology (general, literature) to aid experimental design; it is not product‑specific validation.

• Molecular function:

  • ASAP2 is an Arf GTPase‑activating protein (ArfGAP) that accelerates GTP hydrolysis on ADP‑ribosylation factor (Arf) small GTPases, thereby switching Arf proteins to their inactive GDP‑bound state.
  • Domain architecture typically includes an N‑terminal BAR/ArfGAP module, a PH domain for phosphoinositide binding, ankyrin repeats for protein–protein interactions, and proline‑rich regions that can engage SH3‑domain partners.

• Cellular processes:

  • Membrane trafficking and endocytic recycling via regulation of Arf1/Arf6 activities.
  • Actin cytoskeleton remodeling and cell motility through crosstalk between Arf signaling and actin regulators.
  • Membrane curvature sensing/induction (via BAR/PH elements) and recruitment to PI(4,5)P2‑rich membranes.

• Localization (context‑dependent):

  • Cytosol and membrane compartments including the plasma membrane, endosomes, and Golgi, influenced by phosphoinositide composition and binding partners.

• Experimental implications:

  • Expression and phosphorylation states can be stimulus‑dependent; lysis and fixation conditions affect epitope availability.
  • Knockdown/knockout models and Arf activity assays can complement antibody‑based detection to confirm pathway engagement.

Note: Species reactivity, exact epitope, and application‑specific performance for Ab089761 are Not specified for this item; consult the CoA/Spec Sheet.

Buffer Applications

Buffers are central to reliable antibody performance. Since formulation details are not provided for this SKU, the following are general, literature‑based practices to guide assay setup.

• Common working buffers (general):

  • PBS or TBS, pH 7.2–7.6 for dilutions and washes; add 0.05–0.1% Tween‑20 for WB/IHC/IF to reduce nonspecific binding.
  • Blocking buffers: 5% nonfat dry milk or 3–5% BSA in TBST/PBST for WB; serum‑based or commercial protein blockers for IHC/IF depending on tissue and secondary host.
  • Antigen retrieval (IHC): citrate buffer pH ~6.0 or Tris‑EDTA pH ~9.0, heat‑induced; select empirically.

• Additives and stabilizers (general):

  • Include carrier protein (e.g., 0.1–1% BSA) for low‑concentration working solutions to minimize adsorption.
  • Add sodium azide (0.02–0.05%) only for storage of unconjugated antibodies not used with live cells or HRP‑based detection (azide inhibits HRP).

• Sample preparation (general):

  • WB lysis buffers: RIPA or NP‑40 buffers with protease/phosphatase inhibitors if probing post‑translational states.
  • IF/ICC permeabilization: 0.1–0.3% Triton X‑100 or saponin depending on epitope localization.

Item‑specific recommended buffers, diluents, and retrieval conditions: Not specified for this item; refer to CoA/Spec Sheet.

Green Alternatives

While antibodies themselves are biological reagents, the workflows that use them can be made greener by selecting safer reagents and minimizing hazardous waste.

• Greener practice considerations (general):

  • Blocking and wash buffers: use phosphate‑ or Tris‑based buffers without azides when possible for downstream live‑cell compatibility; prepare concentrates to reduce packaging waste.
  • Detergents: prefer mild, readily biodegradable surfactants at the lowest effective concentration; avoid excessive solvent‑based permeabilization.
  • Detection chemistry: substitute chromogenic substrates requiring heavy metals or toxic developers with aqueous, low‑hazard chemiluminescent/fluorescent systems; dispose of DAB waste as hazardous if used.
  • Imaging and stripping: reduce use of harsh stripping buffers by multiplex fluorescence with spectrally distinct secondaries.
  • Resource efficiency: optimize antibody dilutions to minimize consumption; use reusable cassette systems for IHC to reduce plastic use.

• Comparison snapshot (general):

  • Traditional IHC chromogen (e.g., DAB + metal enhancers): high hazard, hazardous waste.
  • Alternative: aqueous chemiluminescent WB substrates or metal‑free fluorescent dyes: lower hazard, less special waste.

These are general recommendations. Always balance environmental goals with data quality and consult institutional EHS policies.

Pharmaceutical Uses

This product is supplied strictly for research use only (per Product Data) and is not intended for human or veterinary use, diagnostic procedures, or as an active pharmaceutical ingredient.

• Formulation/excipient role: Antibodies of this type are used in research assays (e.g., immunoassays, imaging) rather than as excipients or drug substances in pharmaceutical products.

• Pharmacopeial status: Not applicable; no pharmacopeial monograph is indicated for this research antibody.

• Manufacturing/QC context (general):

  • In bioprocess development, research‑use antibodies may be employed as analytical reagents (e.g., ELISA capture/detection of process impurities or product attributes), but such use requires in‑house qualification and is outside regulated clinical release testing unless validated under GMP.

Any therapeutic, diagnostic, or clinical manufacturing use would require separate sourcing and qualification under appropriate regulatory frameworks; this SKU is not supplied for such purposes.

Physical Properties

Antibodies are macromolecular biologics; many small‑molecule physical constants are not applicable.

• Item-specific properties: Not specified for this item; refer to CoA/Spec Sheet.

• Typical antibody properties (general, literature):

  • Molecular mass: ~150 kDa for full‑length IgG; Fab fragments ~50 kDa; scFv ~25–30 kDa.
  • Isoelectric point (pI): commonly between 6–9, varying by sequence and glycosylation.
  • Solubility: high in aqueous buffered saline (e.g., PBS, TBS) with stabilizers; insoluble in most organic solvents.
  • Stability: enhanced by neutral pH (≈7.2–7.6), protein stabilizers (e.g., BSA), sugars (e.g., trehalose), or 30–50% glycerol for frozen storage; sensitivity to repeated freeze–thaw cycles.
  • Optical properties: A280 for concentration determination using IgG ε ≈ 1.4 (mg/mL)−1 cm−1 (literature average; sequence-specific values may differ).

• Refractive index, logP, melting/boiling points: not meaningful for intact antibodies as formulated aqueous reagents.

Note: For precise concentration, buffer composition, excipients, and formulation of this SKU, consult the product CoA/Spec Sheet. Do not infer small‑molecule parameters (e.g., density, BP, MP) for this biologic material.

Quality and Grades

• Item-specific quality designation (from Product Data):

  • Grade/Purity: ExactAb™, Validated.

• Interpreting these designations (general, for orientation):

  • “Validated” commonly denotes that the antibody has undergone functional testing against defined applications and/or antigens, verifying specificity and performance under stated conditions. Because application details are not provided here, confirm the validated applications for this SKU on the CoA/Spec Sheet.
  • “ExactAb™” identifies the supplier’s antibody line/grade. Without a public standard definition, users should review the accompanying specification sheet for details such as host species, clonality, isotype, concentration, and lot-to-lot consistency criteria.

• What to check on receipt (practical guidance):

  • Documentation: CoA/Spec Sheet for antigen description (protein region/peptide), clonality (mono/polyclonal), host/isotype, concentration, formulation (buffer, stabilizers, preservatives), and recommended applications/dilutions.
  • Physical inspection: solution appearance (clarity, color), container integrity, shipment temperature compliance (shipped on ice packs per Product Data).
  • Performance: run a small pilot titration in your assay matrix; confirm specificity using appropriate controls (positive/negative lysates, peptide block if available).

• UV/LC purity, contaminant limits, and stabilizers: Not specified for this item; refer to CoA/Spec Sheet.

For regulated or quantitative workflows (e.g., QC release assays), maintain the same lot and archive validation data per your lab’s SOPs.

Reaction and Applications

Antibodies are not used as reagents in synthetic chemical reactions; instead, they serve as affinity reagents in bioanalytical applications.

• Typical application families for an anti‑ASAP2 antibody (general guidance; not item‑specific validation):

  • Western blot (WB): detection of ASAP2 in cell/tissue lysates; optimize antibody dilution and antigen retrieval of denatured epitopes.
  • Immunofluorescence (IF)/Immunocytochemistry (ICC): visualization of subcellular localization; fixation/permeabilization conditions can influence epitope exposure (e.g., PFA vs methanol).
  • Immunohistochemistry (IHC): paraffin or frozen sections; antigen retrieval (heat‑induced) may be required depending on epitope.
  • Immunoprecipitation (IP)/Co‑IP: enrichment of ASAP2 and interacting complexes for downstream MS or WB.
  • ELISA: if the antibody recognizes native epitopes, direct/indirect or sandwich formats may be possible with matched pairs.

• Practical tips (general):

  • Start with a dilution series (e.g., 1:200 to 1:2000 for IgG in WB) and titrate to minimize background while maintaining signal.
  • Employ appropriate controls: secondary‑only, isotype controls, ASAP2‑knockdown/knockout lysates, or peptide competition if an immunizing peptide is available.
  • Validate species cross‑reactivity empirically unless specified on the CoA.

Note: Specific validated applications, tested species, and recommended dilutions are Not specified for this item; refer to CoA/Spec Sheet.

Reaction Conditions

Not applicable in the context of chemical synthesis. However, for bioanalytical “reaction‑like” conditions involving antibody–antigen binding (general, literature):

• Temperature: many immunoassays incubate primary antibodies at room temperature for 1–2 h or at 4 °C overnight to enhance specificity.
• Buffer: neutral pH saline buffers (PBS/TBS) with appropriate blockers and detergents tailored to the assay (see Buffer Applications).
• Kinetics: binding is governed by affinity (KD) and on/off rates; extended incubations at lower temperatures can improve signal‑to‑noise for high‑affinity interactions.
• Washing: multiple washes with PBST/TBST reduce background; stringency can be increased by detergent concentration or salt.

Specific incubation times, temperatures, and dilutions validated for this SKU are Not specified for this item; refer to CoA/Spec Sheet.

Safety and Handling

• GHS classification, signal word, pictograms, and H‑statements: Not specified for this item; refer to the SDS for authoritative safety information.

• General laboratory precautions (best practice):

  • Use appropriate PPE: lab coat, nitrile gloves, and safety glasses.
  • Handle as a protein biological reagent; avoid ingestion, inhalation of aerosols, and skin/eye contact. Work in a clean area; use a biosafety cabinet if aerosol generation is possible.
  • Avoid repeated freeze–thaw cycles (per Product Data) to prevent loss of activity and aggregation.
  • Prevent microbial contamination; use sterile tips and containers if sterility is required.

• Incompatibilities and conditions to avoid (general):

  • Avoid extreme pH (<5 or >9) and high temperatures; prolonged exposure to denaturants (e.g., 6–8 M urea, guanidinium) or organic solvents can irreversibly unfold antibodies.
  • Oxidizing agents and proteases may degrade proteins; minimize light exposure if conjugated to fluorophores (not specified for this item).

• First-aid overview (general):

  • Skin/eye contact: Rinse with water for several minutes; remove contaminated clothing. Seek medical attention if irritation persists.
  • Inhalation: Move to fresh air; obtain medical attention if symptoms occur.
  • Ingestion: Rinse mouth; do not induce vomiting; seek medical advice.

Always consult the product SDS and institutional biosafety guidelines for risk assessment and waste disposal.

Solvent Selection

This section is not typically applicable to antibody reagents, which are supplied in aqueous buffers rather than organic solvents.

• Practical guidance (general):
  • Use isotonic aqueous buffers (e.g., PBS, TBS) at neutral pH for dilution and handling. Avoid organic solvents that denature proteins.
  • Additives such as 0.05–0.1% Tween‑20 can reduce nonspecific binding in immunoassays; carrier proteins (e.g., 0.1–1% BSA) can stabilize dilute antibody solutions. These are general practices and should be confirmed against your assay and the product’s CoA.
  • For frozen storage at −20 °C, many labs incorporate 30–50% glycerol to allow storage without ice crystallization; do not implement without confirming formulation compatibility.

For selection of buffers and blocking systems relevant to immunoassays with this antibody, see Buffer Applications.

Storage and Reconstitution

• Storage conditions (from Product Data): Store at −20 °C. Avoid repeated freezing and thawing.

• Shipping condition (from Product Data): Shipped in an ice chest with ice pads.

• Additional item‑specific details (buffer composition, concentration, preservative, reconstitution steps): Not specified for this item; refer to CoA/Spec Sheet.

Handling notes:

• Upon receipt, verify that the package remained cold during transit. Centrifuge briefly to collect contents before opening.
• To comply with “avoid repeated freeze–thaw,” prepare single‑use aliquots immediately after first thaw if the formulation permits. Do not refreeze multiple times.

For any reconstitution instructions (e.g., if supplied lyophilized) and long‑term stability claims, consult the lot‑specific documentation.

Structure and Identity

This product is an antibody reagent directed against the protein ASAP2 (ArfGAP with SH3 domain, Ankyrin repeat and PH domain–containing protein 2). Small‑molecule identifiers (CAS, SMILES, InChIKey) do not apply to antibody biologics.

• Item-specific identifiers (from Product Data):

  • SKU: Ab089761
  • Product Name: ASAP2 Antibody
  • Grade/Purity: ExactAb™, Validated
  • CAS, CID, InChIKey, SMILES: Not applicable to antibodies; not specified for this item; refer to CoA/Spec Sheet.

• Antibody structural features (general, literature):

  • Typical research antibodies are immunoglobulins (e.g., IgG) composed of two heavy and two light chains with disulfide bonds, forming a Y‑shaped heterotetramer (~150 kDa for full-length IgG).
  • Functional regions include the antigen‑binding fragment (Fab; variable domains recognizing the target epitope on ASAP2) and the crystallizable fragment (Fc; mediates effector and secondary detection interactions).

• Target protein context (general, literature):

  • ASAP2 is a member of the Arf GTPase‑activating protein family, characterized by an ArfGAP catalytic domain, adjacent PH (pleckstrin homology) domain for phosphoinositide binding, ankyrin repeats, and often an SH3‑binding region. These domains coordinate membrane association and regulation of Arf‑dependent trafficking and actin remodeling.

• 2D description in words (general):

  • The antibody comprises variable loops (CDRs) within Fab domains that bind an ASAP2 epitope; constant domains form the scaffold. No defined small‑molecule connectivity, rings, or SMILES representation is applicable.

Synthetic Utility

Not applicable. Antibodies are not synthetic building blocks or reagents for chemical transformations. They are affinity reagents for detection, capture, and characterization of biological targets. For practical usage information, see Reaction & Applications and Buffer Applications.

Target Specificity

• Antigen/Target: ASAP2 (ArfGAP with SH3 domain, Ankyrin repeat and PH domain–containing protein 2).
• Epitope, immunogen region/peptide, species reactivity, cross‑reactivity profile, clonality (mono/polyclonal), host species, isotype, and conjugate: Not specified for this item; refer to CoA/Spec Sheet.

Note: Users should verify species reactivity and epitope coverage for their application by consulting the lot‑specific documentation and performing appropriate controls.